Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Majid Hajizadeh Farsani, Amir Hosein Jafari Kashi, Sara Mobarak, Shokrollah Salmanzadeh, Bryony Simmons, Hani Esmaeilian, Andrew Hill, Zahra Lotfi, Morteza Mobarak, Sajedeh Mousaviasl, Ramin Tabibi, Saeid Bitaraf, Gholamali Eslami, Aseni Wickramatillake, Hannah Wentzel, Anahita Sadeghi, Esmat Radmanesh, Seyed Mehdi Talebzadeh, Sedigheh Marjani, Saeed Jelvay, Mahboobeh Momtazan, James Freeman
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the
Autor:
David Hawkins, Amanda Clarke, Gabriel Schembri, Ana Milinkovic, Richard Gilson, Martin Fisher, MiPEP Trial Team, Alejandro Arenas-Pinto, Andrew Williams, Nataliya Brima, P Benn, Andrew Copas
Publikováno v:
The Journal of antimicrobial chemotherapy. 72(6)
OBJECTIVES: Post-exposure prophylaxis (PEP) for HIV is often poorly tolerated and not completed. Alternative PEP regimens may improve adherence and completion, aiding HIV prevention. We conducted a randomized controlled trial of a maraviroc-based PEP
Autor:
Lauren Rose Ammerman, Valentina Stosor, Jennifer Grant, Richard M. Green, Milena M. McLaughlin, Donna V. McGregor, Frank J. Palella, Claudia Hawkins
Publikováno v:
The Journal of antimicrobial chemotherapy. 71(9)
Objectives There are few data on the real-world experience of FDA-approved oral hepatitis C virus (HCV) direct-acting antiviral (DAA) drug combinations in HIV/HCV-coinfected patients. We evaluated the safety and efficacy of DAA therapies in a cohort
Autor:
Lorna, Leal, Agathe, León, Berta, Torres, Alexy, Inciarte, Constanza, Lucero, Josep, Mallolas, Montserrat, Laguno, María, Martínez-Rebollar, Ana, González-Cordón, Christian, Manzardo, Jhon, Rojas, Judit, Pich, Joan A, Arnaiz, Josep M, Gatell, Felipe, García
Publikováno v:
The Journal of antimicrobial chemotherapy. 71(7)
OBJECTIVES The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus maraviroc, both with tenofovir disoproxil/emtricitabine as the backbone. METHODS We conducted
Autor:
A. Benalycherif, Maryvonne Maynart, Mamadou-Baila Diallo, Sinata Koulla-Shiro, A. Ouattara, Charles Kouanfack, F. Ngom Gueye, Mireille Mpoudi Ngolle, S. Koulla-Shiro, Halimatou Diop, P.S. Sow, Aïda Benalycherif, Roland Landman, B. Ndiaye, R. Landman, Moussa Diallo, Ndeye Fatou Ngom Gueye, O. Elad, V. Le Moing, Maguy Ngolle, A. Sock, Claudine Ntsama Essomba, Papa-Salif Sow, Charlotte Charpentier, Sabrina Eymard-Duvernay, M B Koita Fall, E. Simen, P. M. Girard, C. Charpentier, C. Touré Kane, Gilles Peytavin, B. Ymele, Minh Patrick Lê, Avelin F. Aghokeng, S. Eymard-Duvernay, G. Peytavin, Sylvie Legac, Eric Delaporte, A. Thiam, Vincent Le Moing, Pierre-Marie Girard, E. Delaporte
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2015, 70 (5), pp.1517-1521. ⟨10.1093/jac/dku532⟩
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2015, 70 (5), pp.1517-1521. ⟨10.1093/jac/dku532⟩
Objectives An open-label randomized trial (DAYANA) was conducted in sub-Saharan settings to evaluate four different regimens containing tenofovir disoproxil fumarate as first-line treatment for HIV infection. The objectives of the present substudy we
Autor:
Marion Caseris, Patrick Yeni, Roland Landman, Gilles Peytavin, Benoit Visseaux, Yazdan Yazdanpanah, Marion Choquet, Diane Descamps, V Joly, Françoise Brun-Vézinet, Charlotte Charpentier
Publikováno v:
The Journal of antimicrobial chemotherapy. 69(10)
To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification.We enrolled all HIV-1-infecte
Autor:
Stefano Bonora, Marco Simiele, Andrea Galli, Antonio D'Avolio, Giovanni Di Perri, Stefania Chiappetta, Daniel Gonzalez de Requena, Adriano Lazzarin, Andrea Calcagno, Silvia Nozza
Publikováno v:
The Journal of antimicrobial chemotherapy. 68(7)
Autor:
Alan, Winston, Sophie, Jose, Sara, Gibbons, David, Back, Wolfgang, Stohr, Frank, Post, Martin, Fisher, Brian, Gazzard, Mark, Nelson, Richard, Gilson, Chloe, Orkin, Margaret, Johnson, Adrian, Palfreeman, David, Chadwick, Clifford, Leen, Achim, Schwenk, Jane, Anderson, Mark, Gompels, David, Dunn, Saye, Khoo, Caroline, Sabin, Adam, Glabay
Publikováno v:
The Journal of antimicrobial chemotherapy. 68(6)
OBJECTIVES The pharmacokinetic and pharmacodynamic effects of antiretroviral therapy may differ in older compared with younger subjects with HIV infection. We aimed to assess factors associated with plasma antiretroviral drug exposure, including age,
Autor:
Borja Mora-Peris, Alan Winston, Saye Khoo, Laura Else, David Back, Jaime H. Vera, Adam Croucher, George Scullard
Publikováno v:
The Journal of antimicrobial chemotherapy. 68(6)
BACKGROUND Once-daily nucleoside-sparing combination antiretroviral therapy regimens are attractive options for the treatment of HIV infection. However, the pharmacokinetic profiles of such regimens are often not established. METHODS HIV-infected sub
Autor:
Ashini Jayasuriya, Erasmus Smit, Andrew Owen, David Back, Sris Allan, Stephen Taylor, Ed Wilkins, Lisa Heald, Gerry Gilleran, Martin Fisher, Sarah Fidler
Publikováno v:
The Journal of antimicrobial chemotherapy. 67(3)
We designed two different studies to evaluate two different combination antiretroviral therapy (cART) stopping strategies namely a 'staggered stop' approach (STOP 1 study) and a 'protected stop' approach (STOP 2 study) to find the best 'universal sto